S&P 500 7,408 -1.67% Nasdaq 25,138 -2.88% Dow Jones 51,712 -1.60% FTSE 100 10,678 +0.73% DAX 24,981 +0.60% Nikkei 225 64,611 +0.73% Hang Seng 24,963 +1.63% WTI Crude 89.57 +7.62% Gold 4,058 +1.19% US 10-Year Treasury Yield 4.703 +2.28% S&P 500 7,408 -1.67% Nasdaq 25,138 -2.88% Dow Jones 51,712 -1.60% FTSE 100 10,678 +0.73% DAX 24,981 +0.60% Nikkei 225 64,611 +0.73% Hang Seng 24,963 +1.63% WTI Crude 89.57 +7.62% Gold 4,058 +1.19% US 10-Year Treasury Yield 4.703 +2.28%

LATEST

Softbank eyeing acquisition of ETH spinout Gravis, reports suggest●American Express rides a boom in Platinum cards to its strongest spending growth in years●Can AI replace your financial adviser? Why bots still can’t match human judgment.●Odos Protocol to shut down, gives users until July 30 to withdraw assets●EU hits Russia with massive 21st sanctions package targeting $120B crypto network●Burnham urged to lobby EU leaders directly to waive EES border controls●Farmers are already set for a $55 billion payday — why does Washington want to give them even more?●Crypto market maker B2C2 held sale talks with multiple potential buyers●Softbank eyeing acquisition of ETH spinout Gravis, reports suggest●American Express rides a boom in Platinum cards to its strongest spending growth in years●Can AI replace your financial adviser? Why bots still can’t match human judgment.●Odos Protocol to shut down, gives users until July 30 to withdraw assets●EU hits Russia with massive 21st sanctions package targeting $120B crypto network●Burnham urged to lobby EU leaders directly to waive EES border controls●Farmers are already set for a $55 billion payday — why does Washington want to give them even more?●Crypto market maker B2C2 held sale talks with multiple potential buyers●

Markets

Ozempic maker takes biggest rival to court over weight-loss drug ads

TST (Full) - (Official Feed) · 1h ago

Ozempic maker takes biggest rival to court over weight-loss drug ads

Novo Nordisk, the maker of Ozempic, is suing Eli Lilly over advertisements comparing some of their biggest-selling drugs. The ads compare Lilly’s Zepbound with Novo’s Wegovy, and Novo argues they give consumers a misleading picture of how the blockbuster weight-loss drugs stack up. At the center of ...

Read the full story at TST (Full) - (Official Feed) →

More Markets

Cash Value Explained: The “Hidden” Power of Permanent Life Insurance

TST (Full) - (Official Feed) · 1h ago

Target makes another investment in key category it needs to grow

TST (Full) - (Official Feed) · 1h ago

Macy's is selling a diamond bracelet that comes in 3 colors for 75% off

TST (Full) - (Official Feed) · 4h ago

Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off?

MarketBeat News Feed · 5h ago